Figure 1From: Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial Prediction results for patients receiving FEC/TX with and without H treatment. A: ROC curve for TFEC-MGP for all patients who did not receive H treatment. B: ROC for TFEC-MGP for all patients who received H treatment. C: ROC curve for TFEC-MGP for ER-negative patients who did not receive H treatment. D: ROC curve for TFEC-MGP for ER-positive patients who did not receive H treatment.Back to article page